WO2002096367A3 - Targeted multivalent macromolecules - Google Patents

Targeted multivalent macromolecules Download PDF

Info

Publication number
WO2002096367A3
WO2002096367A3 PCT/US2002/017191 US0217191W WO02096367A3 WO 2002096367 A3 WO2002096367 A3 WO 2002096367A3 US 0217191 W US0217191 W US 0217191W WO 02096367 A3 WO02096367 A3 WO 02096367A3
Authority
WO
WIPO (PCT)
Prior art keywords
targeted
macromolecules
linking carrier
multivalent macromolecules
preparation
Prior art date
Application number
PCT/US2002/017191
Other languages
French (fr)
Other versions
WO2002096367A2 (en
Inventor
Narasimhan S Danthi
Steven H Choi
Mark David Bednarski
Charles Aaron Wartchow
Neal Edward Dechene
John S Pease
Zhi Min Shen
Michael Zhang
Julie Trulson
Original Assignee
Targesome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/976,254 external-priority patent/US20020071843A1/en
Application filed by Targesome Inc filed Critical Targesome Inc
Priority to AU2002314861A priority Critical patent/AU2002314861A1/en
Priority to EP02741784A priority patent/EP1401818A2/en
Priority to JP2002592880A priority patent/JP2004535407A/en
Publication of WO2002096367A2 publication Critical patent/WO2002096367A2/en
Publication of WO2002096367A3 publication Critical patent/WO2002096367A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1227—Micelles, e.g. phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

Targeted macromolecules comprising a linking carrier and more than one targeting entityare provided, as well as methods for their preparation and use. Targeted therapeutic agents, comprising a linking carrier, a therapeutic entity associated with the linking carrier, and at least one targeting entity are also provided, as well as methods for their preparation and use.
PCT/US2002/017191 2001-05-30 2002-05-30 Targeted multivalent macromolecules WO2002096367A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2002314861A AU2002314861A1 (en) 2001-05-30 2002-05-30 Targeted multivalent macromolecules
EP02741784A EP1401818A2 (en) 2001-05-30 2002-05-30 Targeted multivalent macromolecules
JP2002592880A JP2004535407A (en) 2001-05-30 2002-05-30 Targeted polyvalent polymer

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US29430901P 2001-05-30 2001-05-30
US60/294,309 2001-05-30
US30910401P 2001-07-31 2001-07-31
US60/309,104 2001-07-31
US31243501P 2001-08-15 2001-08-15
US60/312,435 2001-08-15
US09/976,254 US20020071843A1 (en) 2000-10-11 2001-10-11 Targeted therapeutic agents
US09/976,254 2001-10-11

Publications (2)

Publication Number Publication Date
WO2002096367A2 WO2002096367A2 (en) 2002-12-05
WO2002096367A3 true WO2002096367A3 (en) 2003-03-06

Family

ID=27501629

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/017191 WO2002096367A2 (en) 2001-05-30 2002-05-30 Targeted multivalent macromolecules

Country Status (4)

Country Link
EP (1) EP1401818A2 (en)
JP (1) JP2004535407A (en)
AU (1) AU2002314861A1 (en)
WO (1) WO2002096367A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9295737B2 (en) 2002-03-01 2016-03-29 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US9408926B2 (en) 2002-03-01 2016-08-09 Bracco Suisse S.A. KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US9446155B2 (en) 2002-03-01 2016-09-20 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002245629A1 (en) * 2001-03-08 2002-09-24 Targesome, Inc. Stabilized therapeutic and imaging agents
AU2003212898B2 (en) * 2002-02-01 2008-10-02 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
NZ564694A (en) * 2003-04-22 2009-11-27 Sod Conseils Rech Applic Peptide vectors
ITRM20040240A1 (en) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori CAMPTOTECINE CONJUGATED IN POSITION 7 WITH INTEGRINE ANTAGONISTS.
US8821859B2 (en) * 2004-05-19 2014-09-02 Agency For Science, Technology And Research Methods and articles for the delivery of therapeutic agents
NL1027479C2 (en) * 2004-10-21 2006-05-01 Synvolux Ip B V Protection of biologically active molecules with the help of amphiphiles.
WO2006073314A1 (en) * 2005-01-06 2006-07-13 Ge Healthcare As Optical imaging
WO2007088952A1 (en) * 2006-01-31 2007-08-09 Taiho Pharmaceutical Co., Ltd. Liposome preparation comprising substance having anti-tumor activity
WO2007089043A1 (en) * 2006-02-03 2007-08-09 Takeda Pharmaceutical Company Limited Liposome preparation
EP1985298A1 (en) * 2007-04-24 2008-10-29 Azad Pharma AG Ophtalmic oil-in-water emulsions containing prostaglandins
US8952148B2 (en) 2010-11-23 2015-02-10 Biophore India Pharmaceuticals Pvt Ltd Process for the preparation of taurolidine and its intermediates thereof
EP2537532A1 (en) * 2011-06-22 2012-12-26 J. Stefan Institute Cathepsin-binding compounds bound to a nanodevice and their diagnostic and therapeutic use
JP2014129318A (en) * 2012-02-23 2014-07-10 Canon Inc Indocyanine green-containing particles and photoacoustic-imaging contrast agent including the same
EP2777715A1 (en) * 2013-03-14 2014-09-17 Centre National de la Recherche Scientifique (CNRS) Particles comprising luminescent lanthanide complexes
KR101860117B1 (en) * 2013-12-13 2018-05-21 유겐가이샤 머큐리 에셋 매니지먼트 Articular cartilage imaging composition

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212075A (en) * 1991-04-15 1993-05-18 The Regents Of The University Of California Compositions and methods for introducing effectors to pathogens and cells
US5651986A (en) * 1994-08-02 1997-07-29 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US6066123A (en) * 1998-04-09 2000-05-23 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of bioavailability by use of focused energy delivery to a target tissue
US6132764A (en) * 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212075A (en) * 1991-04-15 1993-05-18 The Regents Of The University Of California Compositions and methods for introducing effectors to pathogens and cells
US5651986A (en) * 1994-08-02 1997-07-29 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US6132764A (en) * 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US6066123A (en) * 1998-04-09 2000-05-23 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of bioavailability by use of focused energy delivery to a target tissue

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9295737B2 (en) 2002-03-01 2016-03-29 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US9381258B2 (en) 2002-03-01 2016-07-05 Bracco Suisse S.A. Targeting vector-phospholipid conjugates
US9408926B2 (en) 2002-03-01 2016-08-09 Bracco Suisse S.A. KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US9446155B2 (en) 2002-03-01 2016-09-20 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy

Also Published As

Publication number Publication date
EP1401818A2 (en) 2004-03-31
WO2002096367A2 (en) 2002-12-05
AU2002314861A1 (en) 2002-12-09
JP2004535407A (en) 2004-11-25

Similar Documents

Publication Publication Date Title
WO2002096367A3 (en) Targeted multivalent macromolecules
AU2003299819A1 (en) Neutrokine-alpha conjugate, neutrokine-alpha complex, and uses thereof
MXPA03007319A (en) Modified anti-egfr antibodies with reduced immunogenicity.
IL160440A0 (en) Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
ZA200104196B (en) Azepinoindole derivatives, the production and use thereof.
WO2003057163A3 (en) Methods for preparing immunoconjugates
IT1316267B1 (en) DOUBLE COUPLING, IN PARTICULAR FOR VEHICLES.
AU2003297318A1 (en) Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
AU2001282108A1 (en) Heterocyclically substituted benzoylcyclohexanediones, methods for producing them and their use as herbicides
AU2003302165A1 (en) Prostate specific antigens, conjugates thereof, methods for their preparation and uses thereof.
AU2003276247A1 (en) Phthalimidyl-azo dyes, process for their preparation and their use
ZA200001746B (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use.
MXPA03006249A (en) 2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them and therapeutic use thereof.
WO2004070009A3 (en) Targeted multivalent macromolecules
MXPA03001783A (en) N-(3,5-dichloro -2-methoxyphenyl) -4-methoxy-3 -piperazin -1-yl- benzenesulfonamide.
AU2002233407A1 (en) 2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them and therapeutic use thereof
ZA200110271B (en) Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylatic methods.
ZA200208346B (en) Polyamide nucleic acid derivatives, agents and methods for producing the same.
AU2001246536A1 (en) Polyamide nucleic acid derivatives, agents and methods for producing the same
IL156162A0 (en) Coniosetin and derivatives thereof, method for producing the same and use thereof.
ZA200002546B (en) Sorbate-preserved compositions, method for the manufacture thereof and their use.
MXPA03006162A (en) Mikanolide derivatives, their preparation and therapeutic uses.
AU2003300262A1 (en) Phthalimidylazo dyes, processes for the preparation thereof and the use thereof
IL161859A0 (en) 3-Heteroaryl-3.5-dihydro-4-oxo-4H-pyridazinoÄ4.5-BÜindole-1-carboxamide derivatives, their preparation and therapeutic use
MXPA02011191A (en) Vaccines, immunotherapeutics and methods for using the same.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2002592880

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002741784

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002741784

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002741784

Country of ref document: EP